DESMODA Drug Patent Profile
When do Desmoda patents expire, and when can generic versions of Desmoda launch?
Desmoda is a drug marketed by Eton and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in DESMODA is desmopressin acetate. There is one drug master file entry for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desmoda
A generic version of DESMODA was approved as desmopressin acetate by MEITHEAL on October 15th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DESMODA?
- What are the global sales for DESMODA?
- What is Average Wholesale Price for DESMODA?
Summary for DESMODA
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DESMODA |
| What excipients (inactive ingredients) are in DESMODA? | DESMODA excipients list |
| DailyMed Link: | DESMODA at DailyMed |
Pharmacology for DESMODA
| Drug Class | Factor VIII Activator Vasopressin Analog |
| Physiological Effect | Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration |
US Patents and Regulatory Information for DESMODA
DESMODA is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eton | DESMODA | desmopressin acetate | SOLUTION;ORAL | 219873-001 | Feb 25, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Eton | DESMODA | desmopressin acetate | SOLUTION;ORAL | 219873-001 | Feb 25, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DESMODA
See the table below for patents covering DESMODA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 4687859 | COMPOSITIONS ORALES DE DESMOPRESSINE (DESMOPRESSIN ORAL COMPOSITIONS) | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2024211393 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DESMODA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2712622 | 122017000006 | Germany | ⤷ Start Trial | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; AUTHORISATION NO/DATE: 94726.00.00 20160901; 94725.00.00 20160901; BE497271 20160504; BE497280 20160504 |
| 2712622 | LUC00015 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101 |
| 3225249 | 300983 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513 |
| 3225249 | CA 2019 00023 | Denmark | ⤷ Start Trial | PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504 |
| 3225249 | 2019C/520 | Belgium | ⤷ Start Trial | PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch